3-Methoxytyramine (3-MT)

Some rare tumors produce dopamine without producing enough adrenaline or noradrenaline to make standard metanephrine tests abnormal. Measuring dopamine's breakdown product, 3-methoxytyramine, can add information in selected cases. The specimen matters: urinary 3-MT has a role in specialist neuroblastoma panels, while plasma free 3-MT is generally more useful for investigating dopamine-producing pheochromocytomas and paragangliomas in adults.

Urinary 3-MT is a specialist adjunct supported by human studies. Its use to predict recurrence or guide treatment is still developing. Published findings apply to the assays and patient groups studied; they don't establish that every commercial urine measurement has the same diagnostic performance.

What Your Result Reflects

Dopamine is a chemical messenger made in the brain and elsewhere in your body. An enzyme called COMT converts some dopamine into 3-MT. This conversion can occur within tumor cells, so a tumor can produce the breakdown product even when dopamine release into the circulation is intermittent.

Urinary 3-MT also includes contributions unrelated to a tumor. Some appears to come from dopamine made within the kidneys from circulating levodopa. Food contributes too. These sources help explain why urinary 3-MT is less effective than plasma free 3-MT at detecting dopamine production by adult tumors.

Urine contains both free 3-MT and forms with an attached chemical group, often sulfate. A free assay measures the unattached form. A total assay first removes those attachments and measures the combined amount. These results describe different fractions and aren't interchangeable.

This test uses liquid chromatography–mass spectrometry, or LC-MS, and reports mcg/g. The supplied test information doesn't specify whether it measures free or total 3-MT, whether collection is timed, or what the gram denominator represents. Many urinary assays report results relative to creatinine, but that detail needs confirmation on this laboratory's report before comparing your number with another assay.

Dopamine-Producing Paragangliomas

Paragangliomas arise from specialized cells associated with nerves in the head, neck, chest, abdomen, or pelvis. A related tumor inside an adrenal gland is called a pheochromocytoma. Many produce adrenaline or noradrenaline, which can cause spells of headache, sweating, pounding heartbeat, and high blood pressure. Head and neck paragangliomas often produce little or none of these hormones. Some produce dopamine, and all pheochromocytomas and paragangliomas have some potential to spread.

An earlier study of 136 adults with head and neck paragangliomas found increased 24-hour urinary 3-MT excretion in 23%. Among those with an increase, 58% had no other abnormal biochemical marker. They also reported more palpitations and sweating. This supports checking dopamine production in selected tumors, but the study's 24-hour excretion results don't establish the detection rate of this mcg/g assay.

For adults, the evidence favors plasma free 3-MT when dopamine production is the question. In a direct comparison using tandem mass spectrometry, it was positive considerably more often than urinary free 3-MT among people with confirmed pheochromocytoma or sympathetic paraganglioma. Urinary total 3-MT detected fewer cases still. These were comparisons of 3-MT alone; standard metanephrine panels performed much better than any isolated 3-MT measurement.

A normal urinary result therefore doesn't exclude a paraganglioma, including a tumor that produces little measurable hormone. People with inherited tumor risk may need imaging even when biochemical tests are normal.

What Higher Levels Say About Tumor Behavior

Studies of plasma free 3-MT have linked higher concentrations with metastatic pheochromocytoma and paraganglioma. Higher plasma levels are also associated with some tumors linked to inherited SDHB variants. SDHB helps cells produce energy, and harmful inherited variants increase susceptibility to these tumors.

These plasma findings concern a different specimen and cannot be applied directly to a urine result. Urinary studies of metastatic disease are much more limited. A raised urinary 3-MT value cannot establish that a tumor has spread, identify its location, or determine which inherited variant you carry.

Neuroblastoma in Children

Neuroblastoma is a cancer of immature nerve cells that mostly affects young children. Urinary homovanillic acid and vanillylmandelic acid, usually shortened to HVA and VMA, are established parts of its diagnostic workup. Adding other dopamine and adrenaline-related compounds can detect cases these two markers miss.

A 2023 study examined urine from 400 children with neuroblastoma and 571 controls. An eight-marker panel including 3-MT detected more cases than HVA and VMA alone. It also flagged more controls without neuroblastoma. The improvement belonged to the whole panel, and came with more false positives.

The same study found similar diagnostic sensitivity with creatinine-corrected spot and 24-hour urine collections. It used both fluorescence-based chromatography and tandem mass spectrometry. Those results support specialist urine panels, but don't prove that this particular assay or collection procedure has equivalent performance.

Retrospective studies have also linked increased urinary 3-MT at diagnosis with high-risk neuroblastoma and poorer survival after accounting for other prognostic factors. In one study, high-risk children older than 18 months with elevated 3-MT had markedly poorer five-year survival than younger high-risk children without the elevation. Those groups differed in age as well as 3-MT, so the comparison doesn't give a survival probability that can be assigned from a urine result alone.

Research comparing urine results with tumor tissue offers a possible explanation. Increased urinary 3-MT was associated with greater activity of the MYC family of growth-regulating genes and less of the enzyme that converts dopamine into noradrenaline. Experiments in neuroblastoma cell lines supported this mechanism. A urine result doesn't replace direct testing of the tumor's biology.

A 2025 retrospective study found that urinary markers could remain abnormal when imaging and bone marrow assessments indicated complete remission. Higher 3-MT at remission was associated with poorer survival, but the estimate was imprecise and urine results were available for only 69 children at that point. The study combined spot and 24-hour specimens and two laboratory methods. It supports investigating urinary markers as additional monitoring tools; it did not show that changing treatment based on 3-MT improves outcomes.

When Results Can Be Misleading

• Free versus total measurement: these assays include different amounts of sulfate-bound 3-MT. The label LC-MS alone doesn't tell you which fraction was measured.
• Food: a controlled human study found that catecholamine-rich nuts and fruits increased both free and total urinary 3-MT. A later, small study found mostly modest effects on urinary free measurements. The size of the change depends on the food, collection period, and assay.
• Levodopa: this Parkinson's medication can greatly increase urinary 3-MT even when measured by mass spectrometry. The drug changes dopamine metabolism, so a more selective analytical method doesn't remove this effect.
• LC-MS limitations: other compounds in urine can weaken the instrument's signal or interfere if they aren't adequately separated. Calibration, sample preparation, and precision at low concentrations also matter. LC-MS reduces many interferences seen with older methods, but doesn't eliminate every source of error.
• Creatinine correction: when results are expressed relative to creatinine, the ratio partly adjusts for urine dilution. It can still be influenced by differences in creatinine production, including age and muscle mass. A ratio alone cannot establish that a timed collection was complete.
• Age and collection conditions: children's urinary results need age-appropriate interpretation. Missed samples, incorrect timing, or unsuitable storage can undermine a collection. Acute illness and severe physical stress can also complicate interpretation of the accompanying catecholamine panel.

Tracking Your Trend

Trends are most informative when a known tumor produced increased urinary 3-MT before treatment. Persistent or rising values can add evidence about ongoing tumor activity, provided the assay and collection conditions remain comparable. A fall is encouraging, but doesn't establish complete remission.

For tumors that never produced much urinary 3-MT, repeated measurements may add little. Imaging and other disease-specific assessments remain necessary. There is no established urinary 3-MT target for longevity, mood, or general wellness.